PROCEPT BioRobotics Corp. is a commercial-stage surgical robotics company, which engages in the development of transformative solutions in urology. It manufactures and sells the AquaBeam Robotic ...
TD Cowen lowered the firm’s price target on Procept BioRobotics (PRCT) to $85 from $99 and keeps a Buy rating on the shares. The firm notes sales topped estimates as the Hydros rollout continues ...
Analysts' ratings for PROCEPT BioRobotics PRCT over the last quarter vary from bullish to bearish, as provided by 4 analysts. The table below provides a concise overview of recent ratings by ...
Morgan Stanley lowered the firm’s price target on Procept BioRobotics (PRCT) to $95 from $105 and keeps an Overweight rating on the shares. Q4 earnings were “better than feared,” with ...
PROCEPT BioRobotics Co. (NASDAQ:PRCT – Free Report) – Investment analysts at William Blair decreased their Q1 2025 earnings per share (EPS) estimates for PROCEPT BioRobotics in a research note ...
PROCEPT BioRobotics Corp. is a commercial-stage surgical robotics company, which engages in the development of transformative solutions in urology. It manufactures and sells the AquaBeam Robotic ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback